A vaccine for breast cancer? Maybe, someday. In The Single Source Cancer Course, Vol 2 we discuss cancer treatments and technologies and analyze the feasibility of developing vaccines.
Research continues around the world with this goal in mind. It appears that great advances are being made in developing a vaccine for women with a particular type of breast cancer that is related to the protein known as human epidermal growth factor receptor-2 or HER-2. The vaccine utilizes a virus known as recombinant adeno-associated virus or AAV.
Unlike other vaccines that have been used primarily in animal studies, AAV has minimal negative effects on human health. Furthermore, AAV is unlike most other viruses in that it survives the human stomach and can move into the bloodstream where it can effectively find its way to cancerous tumors.
Delivered orally, this AAV-based vaccine eventually may be used to prevent other cancers as well, including cancer of the lung. Here’s some additional information: http://lifescientist.com.au/content/health-medical/news/biolife-breast-cancer-vaccine-validated-in-journal-1194536929
Leave a Comment